drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Anti‑HER2 monoclonal antibody that inhibits HER2 signaling and mediates antibody‑dependent cellular cytotoxicity (ADCC).
nci_thesaurus_concept_id
C1647
nci_thesaurus_preferred_term
Trastuzumab
nci_thesaurus_definition
A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)
drug_mesh_term
Trastuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 monoclonal antibody that binds HER2 (ERBB2), blocks receptor dimerization and downstream signaling (e.g., PI3K/AKT, MAPK), promotes receptor internalization/degradation, and engages immune effector cells via Fc to mediate ADCC against HER2‑overexpressing tumor cells.
drug_name
Trastuzumab
nct_id_drug_ref
NCT05982301